Overview

NOVEL THERAPEUTIC ANTIBODIES TO WELL-VALIDATED TARGETS

Bird Rock Bio is a clinical-stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. We are developing first-in-class, best-in-class therapeutic antibodies, with significant clinical and commercial differentiation, against biologic targets with substantial human proof of mechanism.

Our novel biologic therapeutics have the potential to disrupt the industry by providing affordable access to new medicines and addressing emerging disease epidemics to improve health globally.

We are funded by leading biotechnology venture investors, 5AM Ventures, Versant Ventures, Apposite Capital, and Aravis, who are passionate about innovative healthcare.